Interactions between lonidamine and or hydroxypropyl-β-cyclodextrin

Drug Development and Industrial Pharmacy

Volumn 24, Issue 7, 1998, Pages 653-660

  Palmieri, Giovanni Filippo ^a   Wehrlé, Pascal ^b   Martelli, Sante ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; LONIDAMINE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; INDAZOLE DERIVATIVE; WATER;

ARTICLE; BIOAVAILABILITY; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG MIXTURE; DRUG SOLUBILITY; X RAY ANALYSIS; X RAY DIFFRACTION; CHEMISTRY; DRUG INTERACTION; SOLUBILITY;

ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; DRUG INTERACTIONS; INDAZOLES; SOLUBILITY; WATER; X-RAY DIFFRACTION;

EID: 0031593471     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049809082367     Document Type: Article

References (38)

1. I. Shevchuk, V. Chekulayev, J. Moan, and K. Berg, Int. J. Cancer, 67, 791-799 (1996).
2. H. Ben-Horin, M. Tissini, A. Vivi, G. Navon, and O. Kaplan, Cancer Res., 55, 2814-2821 (1995).
3. G. Pratesi, M. De Cesare, and F. Zunino, Cancer Chemother. Pharmacol., 38, 123-128 (1996).
4. L. Orlandi, N. Zaffaroni, D. Gornati, S. Veneroni, and R. Silvestrini, Anticancer Res., 14, 1161-1164 (1994).
5. L. Dogliotti, A. Berruti, T. Buniva, P. Zola, M. G. Bau, A. Farris, M. G. Sarobba, A. Bottini, and P. Alquati, J. Clin. Oncol. 14, 1165-1172 (1996).
6. G. Gardin, C. Barone, O. Nascimben, G. Ianniello, F. Sturba, A. Contu, P. Pronzato, and R. Rosso, Eur. J. Cancer Part A, 32A, 176-177 (1996).
7. M. Lopez, P. Vici, L. Di Lauro, G. Paoletti, T. Gionfra, F. Conti, S. Carpano, F. Pignatti, and D. Giannarelli, Eur. J. Cancer Part A, 31 A, 1611-1614 (1995).
8. G. P. Ianniello, G. De Cataldis, P. Cornella, M. Scarpati Della Vittoria, A. Maiorino, L. Brancaccio, R. Cioffi, A. Lombardi, P. Carnicelli, and V. Tinessa, Cancer, 78, 63-69 (1996).
9. A. Zaniboni, F. Meriggi, A. Alghisi, S. Mutti, L. Distefano, A. Rizzi, L. Bettini, E. Simoncini, and P. Marpicati, Tumori, 81, 435-437 (1995).
10. R. Villa, N. Zaffaroni, L. Orlandi, A. Bearzotto, A. Costa, and R. Silvestrini, Eur. J. Cancer Part A, 30A, 1534-1540 (1994).
11. G. Gardin, C. Barone, O. Nascimben, G. Ianniello, F. Sturba, A. Contu, P. Pronzato, and R. Rosso, Eur. J. Cancer Part A, 32A, 176-177 (1996).
12. D. Del Bufalo, A. Biroccio, S. Soddu, N. Laudonio, C. D'Angelo, A. Sacchi, and G. Zupi, J. Clin. Invest., 98, 1165-1173 (1996).
13. J. H. Kim, S. H. Kim, A. Alfieri, and C. W. Young, US patent 526516, 1993.
14. A. Floridi, F. P. Gentile, T. Bruno, A. Delpino, C. Iacobini, M. G. Paggi, S. Castiglione, and M. Benassi, Oncol. Res., 5, 1-10 (1993).
15. A. Cividalli, F. P. Gentile, L. Begnozzi, L. Chiatti, M. Benassi, and A. Floridi, Int. J. Oncol., 2, 791-795 (1993).
16. G. S. Price, R. L. Page, J. E. Riviere, J. M. Cline, and D. E. Thrall, Cancer Chemother. Pharmacol., 38, 129-135 (1996).
17. S. Z. Lin, D. Wouessidjewe, M. C. Poelman, and D. Duchêne, Int. J. Pharm., 69, 211-219 (1991).
18. C. Torricelli, A. Martini, L. Muggetti, and R. De Ponti, Int. J. Pharm., 71, 19-24 (1991).
19. X. Tan and S. Lindenbaum, Int. J. Pharm., 74, 127-135 (1991).
20. M. G. Fucile, G. Mazzitelli, D. Ratti, and F. Pozzi, Eur. J. Pharm. Biopharm., 38, 140-144 (1992).
21. S. Anguiano-Igea, F. J. Otero-Espinar, J. L. Vila-Jato, and J. Blanco-Méndez, S.T.P. Pharma Sci., 2, 325-331 (1992).
22. G. F. Palmieri, P. Wehrlé, G. Duportail, and A. Stamm, Drug Dev. Ind. Pharm., 18, 2117-2121 (1992).
23. J. Zmitec, D. Kocjan, B. Rusjakowski, N. Bukovec, and P. Bukovec, Acta Pharm., 42, 85-90 (1992).
24. G. F. Palmieri, P. Wehrlé, and A. Stamm, Drug Dev. Ind. Pharm., 19, 875-885 (1993).
25. N. Mulinacci, F. Melani, G. Mazzi, and F. F. Vincieri, Int. J. Pharm., 90, 35-41 (1993).
26. M. Pedersen, M. Edlesten, V. F. Nielsen, A. Scarpelini, S. Skytte, and C. Slot, Int. J. Pharm., 90, 247-254 (1993).
27. M. Pedersen, Drug Dev. Ind. Pharm., 19, 439-448 (1993).
28. M. Skiba, C. Morvan, D. Duchêne, F. Puisieux, and D. Wouessidjewe, Int. J. Pharm., 126, 275-279 (1995).
29. M. Guyot, F. Fawaz, J. Bildet, F. Bonini, and A. M. Lagueny, Int. J. Pharm., 123, 53-63 (1995).
30. G. F. Palmieri, D. Galli-Angeli, G. Giovannuci, and S. Martelli, Drug Dev. Ind. Pharm., 23, 27-37 (1997).
31. G. F. Palmieri, G. Giovannucci, I. Antonini, and S. Martelli, S.T.P. Pharma Sci., 7(2), 174 (1997).
32. M. Krenn, M. P. Gamcsik, G. B. Vogelsang, O. M. Colvin, and K. W. Leong, J. Pharm. Sci., 81, 685-689 (1992).
33. C. J. Betlach, M. A. Gonzalez, B. C. McKiernan, C. Neff-Davis, and N. Bodor, J. Pharm. Sci., 82, 1058-1060 (1993).
34. S. Choudhury and A. K. Mitra, Pharm. Res., 10, 156-159 (1993).
35. K. Csabai, T. Cserháti, and J. Szejtly, Int. J. Pharm., 91, 15-22 (1993).
36. T. Järvinen, K. Järvinen, N. Schwarting, and V. J. Stella, J. Pharm. Sci., 84, 295-299 (1995).
37. U. S. Sharma, S. V. Balasubramanian, and R. M. Straubinger, J. Pharm. Sci., 84, 1223-1230 (1995).
38. T. Higuchi and K. A. Connors, Adv. Anal. Chem. Instr., 4, 117-212 (1965).